Europe
The intention is to focus its research efforts on cancer, immunology, rare diseases and vaccines. The changes will result in the loss of 466 jobs in the two countries.
Bavarian Nordic A/S announced the initiation of a pivotal Phase 3 trial of the freeze-dried formulation of MVA-BN® smallpox vaccine in 1,110 healthy, vaccinia-naïve subjects.
Evotec SE announced that its shareholders approved all proposals the Company’s Management put to vote at the Company’s Annual General Meeting 2019 with very strong supporting majorities.
Balixafortide is the most advanced and only CXCR4 antagonist in development in a pivotal Oncology global registration trial.
Postural sway is an independent risk factor for bone fractures in postmenopausal women, according to a new study from the University of Eastern Finland and Kuopio University Hospital.
Biotech and pharma companies from across Europe and Asia share company and pipeline updates.
Denovo’s new asset will target the Alpha2C adrenoceptor.
The drug showed a statistically significant and clinically meaningful improvement in overall abdominal symptoms compared to placebo for all primary and secondary endpoints.
In North America and across Europe, there is a growing distrust in vaccine safety. France posted the highest mistrust with one-third of people polled.
The facility has acted as one of Bristol-Myers Squibb’s primary launch facilities for new drugs. After the deal is closed, Catalent will continue to manufacture Bristol-Myers Squibb’s current product portfolio at that location.
PRESS RELEASES